EM-113 for Autism - Xiaoming Zhang PhD & Randall Marshall MD - The BRAIN Foundation Synchrony 2023

Xiaoming Zhang PhD, Senior VP of Pharmaceutical Development, and Randall Marshall MD, CEO at Eumentis Therapeutics present on the novel compound EM-113 for ASD patients with elevated glutamate in the anterior cingulate cortex by MR Spectroscopy.
EuMentis Therapeutics Inc. is a clinical stage pharmaceutical company developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with autism who are most likely to benefit.
🎥 This talk was part of Synchrony 2023 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation
🎥 Synchrony 2023 playlist: • Synchrony Symposium 2023
Synchrony brainfoundatio... is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, #pharmaceuticalcompanies and venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.
🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠
The BRAIN Foundation brainfoundatio... is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care. To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.